Mitaclau (Desmopressin)

Desmopressin, the active ingredient in Mitaclau, is a vasopressin analog presented as a sublingual tablet for sublingual use. It is employed to manage central diabetes insipidus, nocturnal enuresis, hemophilia A and von Willebrand disease by enhancing water reabsorption and promoting clotting factor release. GNH USA supplies Mitaclau as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acts on the antidiuretic hormone pathway and is indicated for several endocrine and haemostatic disorders. - Central diabetes insipidus: reduces excessive urine output by increasing renal water reabsorption. - Nocturnal enuresis: decreases nighttime bedwetting episodes in children and adults. - Hemophilia A: raises plasma factor VIII levels to improve clot formation. - von Willebrand disease: enhances release of von Willebrand factor to support platelet adhesion.

Desmopressin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often reported after dosing. - Nausea: transient gastrointestinal discomfort. - Hyponatraemia: mild reduction in serum sodium, usually asymptomatic. - Nasal irritation: when administered intranasally (not typical for sublingual). - Flushing: brief warmth or redness of the skin.

Serious or Rare Side Effects: - Severe hyponatraemia: can lead to seizures, coma, or death. - Water intoxication: excessive fluid retention causing cerebral oedema. - Allergic reactions: rash, pruritus, or anaphylaxis in rare cases. - Thrombotic events: increased risk in patients with pre‑existing clotting disorders. - Hypertensive crisis: rare abrupt rise in blood pressure.

Desmopressin requires careful monitoring to minimise risks. - Monitor serum sodium: check electrolytes regularly, especially in the first days of therapy. - Adjust dose in renal impairment: reduced clearance may heighten hyponatraemia risk. - Limit fluid intake: avoid excessive water consumption while on treatment. - Use caution in the elderly: age‑related renal changes increase susceptibility to adverse effects. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Desmopressin can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: induces hepatic enzymes that reduce desmopressin plasma levels. - Concomitant use with thiazide diuretics: may potentiate water retention and hyponatraemia. - Concomitant use with other antidiuretic agents: risk of severe hyponatraemia.

Moderate Interactions (Monitor Closely): - NSAIDs: can blunt renal prostaglandin synthesis, enhancing antidiuretic effect. - ACE inhibitors or ARBs: may increase risk of low sodium levels. - Selective serotonin reuptake inhibitors (SSRIs): potential additive effect on water balance.